Company Overview and News
UNITED STATES S
2018-09-26 globenewswire - 1
DENVER and VANCOUVER, British Columbia, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sandspring Resources Ltd. (TSX-V: SSP, OTCQX: SSPXF) (the “Company”) is pleased to announce that it has completed an updated Mineral Resource Estimate (the “2018 MRE”) for the Toroparu Project located in Guyana, South America.
WPM SSP SLW MALRY SSPXF MALRF MIN SLW
DENVER and VANCOUVER, British Columbia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Sandspring Resources Ltd. (TSX-V: SSP, OTCQX: SSPXF) (the “Company”) announces that the Company has granted to directors, officers, consultants, employees and charitable organizations options to purchase an aggregate of 7,015,000 common shares of the Company at a price of C$0.24 per share for a period of up to ten years, subject to regulatory approval.
WPM SSP SLW SSPXF SLW
DENVER, Colo. and VANCOUVER, B.C., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Sandspring Resources Ltd. (TSX-V: SSP, OTCQX: SSPXF) (the “Company”) is pleased to provide a corporate update on its current and future activities.
WPM SSP GFI.WI SLW TPWRF GCM SSPXF GCM.WT.A GFI GFIOF SLW TPRFF
2018-09-06 investorplace - 4
While it’s open to debate whether President Donald Trump made America great, the 2016 election did produce one undeniable result: it laid the foundation for cannabis-related businesses, thereby dramatically improving profitability potential for marijuana penny stocks.
WPM CBWTF CBIS STZ.B STNY SLW CRON STZ TLRY SLW
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
2018-08-06 seekingalpha - 2
Cobalt is an essential ingredient for Lithium-ion batteries. Supply is tight and getting tighter. Gaining meaningful direct exposure to cobalt is near-impossible to achieve.
WPM SAND SSL SDDXF ABX OKSWF SNXZF SLW RGLD HIG RNX RNX.WT CBLLF SLW RNKLF KNTNF OR HLPCF OSKGF SCYYF SCY RGL ABX
UNITED STATES S
Wheaton Precious Metals Corp.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 July 16, 2018 Commission File Number: 001-32482
We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
WPM NGD GFI.WI ABX NEM NGDAF K GDX NGD SLW SLW ELD KGC GFI GFIOF EGO ABX
Editor’s note: Below, you’ll find the latest essay in Matt McCall’s series on how to make money during the coming marijuana boom. In this essay, Matt reveals what could turn out to be the ultimate way to invest in legal marijuana.
RGLD FNV.WT.A SLW FNV SLW FNV RGL
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to SLW / Silver Wheaton Corp. on message board site Silicon Investor.
as of ET